Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.
Cunningham CE, Vizeacoumar FS, Zhang Y, Kyrylenko L, Both S, Maranda V, Dong H, Price JDW, Gao P, Wagner K, Wu Y, Lazell-Wright M, Ganapathysamy A, Hari R, Bhanumathy KK, Denomy C, Saxena A, Vizeacoumar JP, Morales AM, Khan F, Mosley S, Chen A, Katrii T, Zoller BGE, Rajamanickam K, Walke P, Gong L, Patel H, Elhasasna H, Dahiya R, Abuhussein O, Dmitriev A, Freywald T, Munhoz EP, Ruppin E, Lee JS, Rox K, Koebel M, Hopkins L, Lee CH, Yadav S, Gasparoni G, Walter J, Krishnan A, Datla R, Toosi B, Baker K, Meens J, Cescon DW, Ailles L, Leary SC, Wu Y, Empting M, Kiemer AK, Freywald A, Vizeacoumar FJ.
Cunningham CE, et al. Among authors: lee js.
Cell Genom. 2025 May 7:100876. doi: 10.1016/j.xgen.2025.100876. Online ahead of print.
Cell Genom. 2025.
PMID: 40347943